Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZF8F
|
|||
| Former ID |
DNCL002861
|
|||
| Drug Name |
HIP-2B
|
|||
| Indication | Type-1/2 diabetes [ICD-11: 5A10-5A11] | Phase 1 | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [2] | ||
| Company |
CureDM
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Regenerating human pro-islet peptide (REG3A) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01933256) Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol.1999 Nov;155(5):1525-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.